Three-Dimentional Quantitative Structure-Activity Relationships of ATP-Sensitive Potassium (KATP) Channel Openers Belonging to the 3-Alkylamino-4H-1,2,4-benzo- and 3-Alkylamino-4H-1,2,4-pyridothiadiazine 1,1-Dioxide Families
De Tullio, Pascal; Dupont, L.; Francotte, Pierreet al.
2006 • In Journal of Medicinal Chemistry, 49, p. 6779-6788
De Tullio, Pascal ; Université de Liège - ULiège > Département de pharmacie > Chimie pharmaceutique
Dupont, L.
Francotte, Pierre ; Université de Liège - ULiège > Département de pharmacie > Chimie pharmaceutique
Counerotte, Stéphane ; Université de Liège - ULiège > Département de pharmacie > Chimie pharmaceutique
Lebrun, P.
Pirotte, Bernard ; Université de Liège - ULiège > Département de pharmacie > Chimie pharmaceutique
Language :
English
Title :
Three-Dimentional Quantitative Structure-Activity Relationships of ATP-Sensitive Potassium (KATP) Channel Openers Belonging to the 3-Alkylamino-4H-1,2,4-benzo- and 3-Alkylamino-4H-1,2,4-pyridothiadiazine 1,1-Dioxide Families
Publication date :
2006
Journal title :
Journal of Medicinal Chemistry
ISSN :
0022-2623
eISSN :
1520-4804
Publisher :
American Chemical Society, Washington, United States - District of Columbia
Noma, A. ATP-regulated K+ channels in cardiac muscle. Nature 1983, 305, 147-148.
Cook, D. L.; Hales, C. N. Intracellular ATP directly blocks K+ channels in pancreatic B-cells. Nature 1984, 311, 271-273.
Bernardi, H.; Fosset, M.; Lazdunski, M. Purification and affinity labeling of brain [3H] glibenclamide binding protein, a putative neuronal ATP-regulated K+ channel. Proc. Natl. Acad. Sci. U.S.A. 1988, 85, 9816-9820.
Standen, N. B.; Quayle, J. M.; Davies, N. W.; Brayden, J. E.; Huang, Y.; Nelson, M. T. Hyperpolarizing vasodilators activate ATP-sensitive K+ channels in arterial smooth muscle. Science 1989, 245, 177-180.
Allard, B.; Lazdunski, M. Pharmacological properties of ATP-sensitive K+ channels in mammalian skeletal muscle cells. Eur. J. Pharmacol. 1993, 236, 419-426.
Quayle, J. M.; Nelson, M. T.; Standen, N. B. ATP-sensitive and inwardly rectifying potassium channels in smooth muscle. Physiol. Rev. 1997, 77, 1165-1232.
Bryan, J.; Aguilar-Bryan, L. The ABCs of ATP-sensitive potassium channels: More pieces of the puzzle. Curr. Opin. Cell Biol. 1997, 9, 553-559.
Seino, S.; Miki, T. Physiological and pathophysiological roles of ATP-sensitive K+ channels. Prog. Biophys. Mol. Biol. 2003, 81, 133-176.
Babenko, A. P.; Aguilar-Bryan, J. A. A view of SUR/Kir6.X KATP channels. Annu. Rev. Physiol. 1998, 60, 667-687.
D'hahan, N.; Jacquet, H.; Moreau, C.; Catty, P.; Vivaudou, M. A transmembrane domain of the sulfonylurea receptor mediates activation of ATP-sensitive K+ channels by K+ channel openers. Mol. Pharmacol. 1999, 56, 308-315.
Seino, S. ATP-sensitive potassium channels: a model of heteromultimeric potassium channel/receptor assemblies. Annu. Rev. Physiol. 1999, 61, 337-362.
Inagaki, N.; Gonio, T.; Clement, J. P. Reconstitution of I KATP: An inward rectifier subunit plus a sulfonylurea receptor. Science 1995, 270, 1166-1170.
Hambrock, A.; Löffler-Walz, C.; Kloor, D.; Delabar, U.; Horio, Y.; Kurachi, Y.; Quast, U. ATP-sensitive K+ channel modulator binding to sulfonylurea receptors SUR2A and SUR2B: Opposite effects of MgADP. Mol. Pharmacol. 1999, 55, 832-840.
Petersen, O. H.; Dunne, M. J. Regulation of K+ channels plays a crucial role in the control of insulin secretion. Pflüegers Arch. 1989, 414, S115-S120.
Lebrun, P. Flux cationiques dans les cellules B des îlots pancréatiques et investigations pharmacologiques. Rev. Fr. Endocrinol. Clin. 1993, 34, 241-254.
Kolb, H. A. Potassium channels in excitable and non-excitable cells. Rev. Physiol. Biochem. Pharmacol. 1990, 15, 51-79.
Brayden, J. E. Functional roles of KATP channels in vascular smooth muscles. Clin. Exp. Pharmacol. Physiol. 2002, 29, 312-316.
Seino, S.; Miki, T. Physiological and pathophysiological roles of ATP-sensitive K+ channels. Prog. Biophys. Mol. Biol. 2003, 81, 133-176.
Coghlan, M. J.; Carroll, W. A.; Gopalakrishnan, M. Recent developments in the biology and medicinal chemistry of potassium channel modulators: Update from a decade of progress. J. Med. Chem. 2001, 44, 1627-1653.
Lebrun, P.; Devreux, V.; Hermann, M.; Herchuelz, A. Similarities between the effects of pinacidil and diazoxide on ionic and secretory events in rat pancreatic islets. J. Pharmacol. Exp. Ther. 1989, 250, 1011-1018.
Quast, U. Do the K+ channel openers relax smooth muscle by opening K+ channels? Trends Pharmacol. Sci. 1993, 14, 332-337.
Mannhold, R. KATP channel openers: Structure-activity relationships and therapeutic potential. Med. Res. Rev. 2004, 24, 213-266.
Björk, E,; Berne, C.; Kämpe, O.; Wibell, P.; Oskarsson, P.; Karlsson, F. A. Diazoxide treatment at onset preserves residual insulin secretion in adults with autoimmune diabetes. Diabetes 1996, 45, 1427-1430,
Alemzadeh, R.; Langley, G.; Upchurch, L.; Smith, P.; Slonim, A. E. Beneficial effect of diazoxide in obese hyperinsulinemic adults. J. Clin. Endocrinol. Metab. 1998, 83, 1911-1915.
Rasmussen, S. B.; Sorensen, T. S.; Hansen, J. B.; Mandrup-Poulsen, T.; Hornum, L.; Markholst, H. Functional rest through intensive treatment with insulin and potassium channel openers preserves residual beta-cells function and mass in acutely diabetic BB rats. Horm. Metab. Res. 2000, 32, 294-300.
Ritzel, R. A.; Hansen, J. B.; Veldhuis, J. D.; Butler, P. C. Induction of beta-cell rest by a Kir6.2/SUR1-selective K(ATP)-channel opener preserves beta-cell insulin stores and insulin secretion in human islets cultured at high (11 mM) glucose. J. Clin. Endocrinol. Metab. 2004, 89, 795-805.
Kumar, G. K.; Dastoor, F. C.; Robayo, J. R.; Razzaque, M. A. Side effects of diazoxide. JAMA, J. Am. Med. Assoc. 1976, 235, 275-276.
de Tullio, P.; Pirotte, B.; Lebrun, P.; Fontaine, J.; Dupont, L.; Antoine, M.-H.; Ouedraogo, R.; Khelili, S.; Maggetto, C.; Masereel, B.; Diouf, O.; Podona, T.; Delarge, J. 3- and 4-Substituted 4H-pyrido[4,3-e]-1,2,4- thiadiazine 1,1-dioxides as potassium channel openers: Synthesis, pharmacological evaluation and structure-activity relationships. J. Med. Chem. 1996, 39, 937-948.
de Tullio, P.; Ouedraogo, R.; Dupont, L.; Somers, F.; Boverie, S.; Dogné, J.-M.; Delarge, J.; Pirotte, B. Synthesis and structural studies of 3-alkylamino-pyrido[4,3-e]-1,2,4-thiadiazine 1,1-dioxides, a new class of heterocyclic compounds with therapeutic promises. Tetrahedron 1999, 55, 5419-5432.
Pirotte, B.; Ouedraogo, R.; de Tullio, P.; Khelili, S.; Somers, F.; Boverie, S.; Dupont, L.; Fontaine, J.; Damas, J.; Lebrun, P. 3-Alkylamino-4H-pyrido[2,3-e]-1,2,4-thiadiazine 1,1-dioxides structurally related to diazoxide and pinacidil as potassium channel openers acting on vascular smooth muscle cells: Design, synthesis, and pharmacological evaluation. J. Med. Chem. 2000, 43, 1456-1466.
Boverie, S.; Antoine, M.-H.; de Tullio, P.; Somers, F.; Becker, B.; Sebille, S.; Lebrun, P.; Pirotte, B. Effect on insulin release of compounds structurally related to the potassium-channel opener 7-chloro-3-isopropylamino- 4H-1,2,4-benzothiadiazine 1,1-dioxide (BPDZ 73): Introduction of heteroatoms on the 3-alkylamino side chain of the benzothiadiazine 1,1-dioxide ring. J. Pharm. Pharmacol. 2001, 53, 973-980.
Ouedraogo, R.; Becker, B.; Boverie, S.; Somers, F.; Antoine, M.-H.; Pirotte, B.; Lebrun, P.; de Tullio, P. 2-Alkyl-3-alkylamino-2H-benzo- and pyridothiadiazine 1,1-dioxides: From K+ATP channel openers to Ca2+ channel blockers? Biol. Chem. 2002, 383, 1759-1768.
de Tullio, P.; Becker, B.; Boverie, S.; Dabrowski, M.; Wahl, P.; Antoine, M.-H.; Somers, F.; Sebille, S.; Ouedraogo, R.; Bondo Hansen, J.; Lebrun, P.; Pirotte, P. Toward tissue-selective pancreatic B-cells KATP channel openers belonging to 3-alkylamino-7-halo-4H-1,2,4-benzothiadiazine 1,1-dioxides. J. Med. Chem. 2003, 46, 3342-3353.
Boverie, S.; Antoine, M.-H.; Somers, F.; Becker, B.; Sebille, S.; Ouedraogo, R.; Counerotte, S.; Pirotte, B.; Lebrun, P.; de Tullio, P. Effect on KATP channel activation properties and tissue selectivity of the nature of the substituent in the 7- and the 3-position of 4H-1,2,4- benzothiadiazine 1,1-dioxides. J. Med. Chem. 2005, 48, 3492-3503.
de Tullio, P.; Boverie, S.; Becker, B.; Antoine, M.-H.; Nguyen, Q.-A.; Francotte, P.; Counerotte, S.; Sebille, S.; Pirotte, B.; Lebrun, P. 3-Alkylamino-4H-1,2,4-benzothiadiazine 1,1-dioxides as ATP-sensitive potassium channel openers: Effect of 6,7-disubstitution on potency and tissue selectivity. J. Med. Chem. 2005, 48, 4990-5000.
Pirotte, B.; Antoine, M.-H.; de Tullio, P.; Hermann, M.; Herchuelz, A.; Delarge, J.; Lebrun, P. A pyridothiadiazine (BPDZ 44) as a new and potent activator of ATP-sensitive K+ channels. Biochem. Pharmacol. 1994, 47, 1381-1386.
Lebrun, P.; Arkhammar, P.; Antoine, M.-H.; Nguyen, Q.-A.; Bondo Hansen, J.; Pirotte, B. A potent diazoxide analogue activating ATP-sensitive K + channels and inhibiting insulin release. Diabelologia 2000, 43, 723-732.
Cosgrove, K.; Antoine, M.-H.; Lee, A.; Barnes, P.; de Tullio, P.; Clayton, P.; McCloy, R.; De Lonlay, P.; Nihoul-Fékété, C.; Robert, J.; Saudubray, J.-M.; Rahier, J.; Lindley, K.; Hussain, K.; Aynsley-Green, A.; Pirotte, B.; Lebrun, P.; Dunne, M. BPDZ 154 activates adenosine 5′-triphosphate-sensitive potassium channels: In vitro studies using rodent insulin-secreting cells and islets isolated from patients with hyperinsulinism. J. Clin. Endocrinol. Metab. 2002, 87, 4860-4868.
Dabrowski, M.; Ashcroft, F. M.; Ashfield, R.; Lebrun, P.; Pirotte, B.; Egebjerg, J.; Hansen J. B.; Wahl, P. The novel diazoxide analog 3-isopropylamino-7-methoxy-4H-1,2,4-benzothiadiazine 1,1-dioxide is a selective Kir6.2/SUR1 channel opener. Diabetes 2002, 51, 1896-1906.
Nielsen, F. E.; Bodvarsdottir, T. B.; Worsaae, A.; MacKay, P.; Stidsen, C. E.; Boonen, H. C.; Pridal, L.; Arkhammar, P. O. G.; Whal, P.; Ynddal, L.; Junager, F.; Dragsted, N.; Tagmose, T. M.; Mogensen, J. P.; Koch, A.; Treppendahl, S. P.; Hansen, J. B. 6-Chloro-3-alkylamino-4H-thieno[3,2-e]-1,2,4- benzothiadiazine 1,1-dioxide derivatives potently and selectively activate ATP sensitive potassium channels of pancreatic beta-cells. J. Med. Chem. 2002, 45, 4171-4187.
Pirotte, B.; de Tullio, P.; Antoine, M.-H.; Sebille, S.; Florence, X.; Lebrun, P. New insights into the development of ATP-sensitive potassium channel openers. Expert Opin. Ther. Patents 2005, 15, 497-504.
Sybyl 7.0; Tripos Associates, Inc.: St. Louis, MO, 2004.
Stewart, J. J. MOPAC, a Semiempirical Molecular Orbital Program. J. Comput.-Aided Mol. Des. 1990, 4, 1-105.
Khelili, S.; de Tullio, P.; Lebrun, P.; Fillet, M.; Antoine, M.-H.; Ouedraogo, R.; Dupont, L.; Fontaine, J.; Felekidis, A.; Leclerc, G.; Delarge, J.; Pirotte, B. Preparation and pharmacological evaluation of the R- and S-enantiomers of 3-(2′-butylamino)-4H- and 3-(3′-methyl-2- butylamino)-4H-pyrido[4,3-e]-1,2,4-thiadiazine 1,1-dioxide, two tissue selective ATP-sensitive potassium channel openers. Bioorg. Med. Chem. 1999, 7, 1513-1520.
Cramer, R. D., III; Bunce, J. D.; Patterson, D. E. Crossvalidation, bootstrapping, and partial least squares compared with multiple regression in conventional QSAR studies. Quant. Struct.-Act. Relat. 1988, 7, 18-25.
